Drug Profile
Melanoma vaccine - Bavarian Nordic
Alternative Names: MVA - malignant melanoma; MVA-BN tyrLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Bavarian Nordic; BN ImmunoTherapeutics
- Developer Bavarian Nordic
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 15 Nov 2005 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
- 22 Dec 2004 Preclinical trials in Malignant melanoma in USA (unspecified route)
- 23 Aug 2002 Discontinued - Phase-II for Malignant melanoma in Germany (Intradermal)